Article Sidebar
Views pdf: 86
RESULTS OF CONCURRENT CHEMORADIATION FOR LIMITED-STAGE SMALL CELL LUNG CANCER PATIENTS AT K HOSPITAL
Main Article Content
Abstract
Objectives: to evaluate initial results of concurrent chemoradiation for limited-stage small cell lung cancer. Methods: Clinical trial, no control group. From January 2015 to January 2019, we enrolled 45 limited-stage small cell lung cancer. All patients were treated concurrent chemoradiation – thoracic RT 60Gy – 2Gy/fraction plus Etoposide-Cisplatin x 4 cycles. We assessed response rate and toxicity. Results: Clinical features: median of age 46,1. Chest pain is the most common symptoms (37,8%). The average tumor size is 2.6cm. Mediastinal node metastasis rate was 68,9%. Small cell carcinoma has highest rate 95,6%. Efficacy: 91,2% of patients were treated with 85-100% standard dose of chemotherapy. Overall response rate was 97,8%. Complete response rate was high with 97,8%. Treatment was well tolerated. The most common toxicity was neutropenia, almost grade I and II, other toxicities were less common. Heart failure and lung fibrosis was 2,2% and mild with no symptoms. Conclusion: Concurrent chemoradiation for limited-stage small cell lung cancer is feasible and high efficacy.
Article Details
Keywords
Limited-stage small-cell lung cancer, concurrent chemoradiation
References
2. International Agency for Research on Cancer World Health Organization (2013), GLOBOCAN 2012: Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012. Lung Cancer, truy cập ngày-2013, tại trang web http:// globocan.iarc.fr/Pages/fact_sheets_cancer.aspx.
3. LM Krug, MC Pietanza andMG Kris (2011), "Small cell and other neuroendocrine tumors of the lung", DeVita, Hellman and Rosenberg's CancerPrinciple and Practice of Oncology, Lippincott Williams & Wilkins, Philadelphia, 848-870.
4. DeVita Hellman & Rosenberg's (2015), Cancer-Principles & Practice of Oncology 10, LWW, New York.
5. Phạm Nguyên Cường (2015), Nghiên cứu phân loại mô bệnh học ung thư biểu mô phổi theo WHO 2004 và IASLC/ATS/ERS 2011 có sử dụng dấu ấn hóa mô miễn dịch, Trường Đại học Y Hà Nội.
6. Kubota K., Hida T., Ishikura S. et al (2014), Etoposide and cisplatin versus irinotecan and cisplatin in patients with limited-stage small-cell lung cancer treated with etoposide and cisplatin plus concurrent accelerated hyperfractionated thoracic radiotherapy (JCOG0202): a randomised phase 3 study, Lancet Oncol. 15(1), 106-13.
7. Võ Văn Xuân (2009), Nghiên cứu áp dụng phác đồ kết hợp hóa - xạ trị trong ung thư phổi tế bào nhỏ và đánh giá kết quả điều trị, Đại học Y Hà Nội.
8. De Ruysscher D., Lueza B., Le Pechoux C. et al (2016), Impact of thoracic radiotherapy timing in limited-stage small-cell lung cancer: usefulness of the individual patient data meta-analysis, Ann Oncol. 27(10), 1818-28.